Complementary institutions have joined Open Targets and are working together to improve how we systematically identify and prioritise drug targets. Working together, they can focus their expertise to build resources and projects that are greater than the sum of their parts.

Are you interested in joining the Open Targets partnership? If so, contact us!

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases ... read more

The European Bioinformatics Institute (EMBL-EBI) is a global leader in the management, integration, and analysis of life science data ... read more

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases ... read more

GSK is a global pharmaceutical company that has developed some of the most successful drugs of the past three decades ... read more

Pfizer is one of the world's premier biopharmaceutical companies that has developed innovative therapies and vaccines that change patients' lives and make the world a healthier place ... read more

Sanofi is a global biopharmaceutical company focussed on human health and transforming scientific innovation into healthcare solutions around the globe ... read more

The Wellcome Sanger Institute is a world-leading genomics institution with expertise in human genetics, cancer, and infectious disease ... read more

We also collaborate with other groups with similar philosophies and complementary expertise on specific projects where we believe the collaboration will be impactful. Currently we are working with the UKDRI and the Medical School at the University of Cambridge, University College London, the University of Tartu, and the University of Oxford among others. Biogen was a member of Open Targets between 2016 and 2020 engaging in a programme of neurodegeneration projects with us. Takeda was also a member of Open Targets between 2017 and 2020 collaborating on a range of experimental and informatics projects across our focus therapeutic areas.